JP2019528285A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528285A5 JP2019528285A5 JP2019509555A JP2019509555A JP2019528285A5 JP 2019528285 A5 JP2019528285 A5 JP 2019528285A5 JP 2019509555 A JP2019509555 A JP 2019509555A JP 2019509555 A JP2019509555 A JP 2019509555A JP 2019528285 A5 JP2019528285 A5 JP 2019528285A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- human patient
- disease
- crohn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377358P | 2016-08-19 | 2016-08-19 | |
| US62/377,358 | 2016-08-19 | ||
| PCT/US2017/047357 WO2018035330A1 (en) | 2016-08-19 | 2017-08-17 | Methods of treating crohn's disease with an anti-nkg2d antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019528285A JP2019528285A (ja) | 2019-10-10 |
| JP2019528285A5 true JP2019528285A5 (enExample) | 2020-08-27 |
Family
ID=61197073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019509555A Pending JP2019528285A (ja) | 2016-08-19 | 2017-08-17 | 抗ｎｋｇ２ｄ抗体を用いたクローン病の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190292265A1 (enExample) |
| EP (1) | EP3500293A4 (enExample) |
| JP (1) | JP2019528285A (enExample) |
| KR (1) | KR20190038919A (enExample) |
| AU (1) | AU2017312049A1 (enExample) |
| CA (1) | CA3034324A1 (enExample) |
| MA (1) | MA45997A (enExample) |
| MX (1) | MX2019001958A (enExample) |
| WO (1) | WO2018035330A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CA3099308A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
| US12264368B2 (en) | 2018-07-06 | 2025-04-01 | Cedars-Sinai Medical Center | Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures |
| BR112021012066A2 (pt) | 2018-12-21 | 2021-11-03 | Onxeo | Novas moléculas de ácido nucleico conjugadas e seus usos |
| TW202515610A (zh) * | 2019-04-22 | 2025-04-16 | 美商美國禮來大藥廠 | 治療克隆氏症(crohn's disease)的方法 |
| WO2021057988A1 (zh) * | 2019-09-27 | 2021-04-01 | 廖睿 | 检测粪钙卫蛋白含量的试剂在制备输卵管病变筛查试剂盒中的用途 |
| TW202214857A (zh) | 2020-06-19 | 2022-04-16 | 法商昂席歐公司 | 新型結合核酸分子及其用途 |
| CN116199777B (zh) * | 2021-12-01 | 2025-01-28 | 北京免疫方舟医药科技有限公司 | 抗hNKG2D抗体及其应用 |
| KR20240133795A (ko) | 2021-12-16 | 2024-09-04 | 발레리오 테라퓨틱스 | 신규한 컨쥬게이티드 핵산 분자 및 이의 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050266432A1 (en) * | 2004-02-26 | 2005-12-01 | Illumina, Inc. | Haplotype markers for diagnosing susceptibility to immunological conditions |
| AU2008337517B2 (en) * | 2007-12-14 | 2014-06-26 | Novo Nordisk A/S | Antibodies against human NKG2D and uses thereof |
| PL2458992T3 (pl) * | 2009-07-30 | 2016-07-29 | Teva Pharma | Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu |
| EP2519653A4 (en) * | 2009-12-31 | 2013-07-10 | Univ Columbia | METHOD FOR DETECTING AND REGULATING CIRCULAR HAIR LOSS AND GENKOHORTAS THEREOF |
| BR112017013981A2 (pt) * | 2015-01-26 | 2018-01-02 | Cellectis | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer |
-
2017
- 2017-08-17 US US16/325,969 patent/US20190292265A1/en not_active Abandoned
- 2017-08-17 JP JP2019509555A patent/JP2019528285A/ja active Pending
- 2017-08-17 AU AU2017312049A patent/AU2017312049A1/en not_active Abandoned
- 2017-08-17 WO PCT/US2017/047357 patent/WO2018035330A1/en not_active Ceased
- 2017-08-17 MX MX2019001958A patent/MX2019001958A/es unknown
- 2017-08-17 KR KR1020197007550A patent/KR20190038919A/ko not_active Ceased
- 2017-08-17 MA MA045997A patent/MA45997A/fr unknown
- 2017-08-17 CA CA3034324A patent/CA3034324A1/en not_active Abandoned
- 2017-08-17 EP EP17842125.1A patent/EP3500293A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528285A5 (enExample) | ||
| JP6877357B2 (ja) | Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法 | |
| JP2018512435A5 (enExample) | ||
| JP2020002171A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| JP2014530226A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2014515763A5 (enExample) | ||
| JP2015514110A5 (enExample) | ||
| JP2016538277A5 (enExample) | ||
| JP2016501892A5 (enExample) | ||
| JP2014519487A5 (enExample) | ||
| AR088458A1 (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod | |
| JP2013542194A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| JP2017537105A5 (enExample) | ||
| JP2019505527A5 (enExample) | ||
| JP2015505564A5 (enExample) | ||
| JP2019528306A5 (enExample) | ||
| JP2010500370A5 (enExample) | ||
| JP2022531408A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| RU2017100077A (ru) | Способы лечения ттп иммуноглобулиновыми одиночными вариабельными доменами и их применение | |
| JP2017519762A5 (enExample) | ||
| JP2020521761A5 (enExample) |